Showing 8101-8110 of 8896 results for "".
- FDA Greenlights First-Ever OTC Retinoidhttps://practicaldermatology.com/news/fda-greenlights-first-ever-otc-retinoid/2458507/The U.S. Food and Drug Administration (FDA) approved Differin Gel 0.1% (adapalene), a once-daily topical gel for the over-the-counter (OTC) treatment of acne in people 12 years of age and older. Differin Gel 0.1% is the first retinoid to be made available OTC for the
- Some Fan-Favorite Sunscreens Don't Adhere to AAD Guidelineshttps://practicaldermatology.com/news/some-fan-favorite-sunscreens-dont-adhere-to-aad-guidelines/2458509/While consumers give rave reviews to some sunscreens, many of these products do not meet American Academy of Dermatology (AAD) guidelines, according to a new article published online by JAMA Dermatology.
- Sciton Launches New Program to Encourage Practice Growthhttps://practicaldermatology.com/news/sciton-launches-new-program-to-encourage-practice-growth/2458510/Sciton Inc. is unveiling their new practice support program. With Success Builder, Sciton offers four specialized pillars: clinical training, marketing tools, business development, and Sciton-sanctioned tools and courses. Many of the vendors also o
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme
- Global Psoriasis Survey: 85% of US Respondents Faced Social Stigma Because of Psoriasishttps://practicaldermatology.com/news/global-psoriasis-survey-85-of-us-respondents-faced-social-stigma-because-of-psoriasis/2458514/Novartis released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85 percent of US respondents have suffered from social stigma like discrimination and humiliation because of their disease. In additi
- Daily ‘Soak and Smear' OKed for Kids with Eczemahttps://practicaldermatology.com/news/daily-soak-and-smear-oked-for-kids-with-eczema/2458513/Daily bathing is fine for children with eczema as long as it's followed by lots of moisturizer, according to a new article in Annals of Allergy, Asthma and Immunology. Researchers led by Portl
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Regenica® Rejuvenating Dual Serum Improves Skin Texture, Tone Through 90 Dayshttps://practicaldermatology.com/news/regenica-rejuvenating-dual-serum-improves-skin-texture-tone-through-90-days/2458521/New research shows that Regenica® Rejuvenating Dual Serum starts working at as early as 14 days, with continued improvement seen through 90 days. In the study, statistically significant improvements were reported as early as 14 days, wi
- Alopecia Areata May Protect Against Stroke, Heart Attackhttps://practicaldermatology.com/news/alopecia-areata-may-protect-against-stroke-heart-attack/2458522/Unlike other inflammatory dermatologic conditions, alopecia areata does not appear to increase risk for cardiovascular disease, and it may even protect against stroke, new research suggests. Researchers compared 1,377 alopecia areata patients to 4,131 control subjects. They found th